Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16431614 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1GAAHPGDUSP2 | |
| SCHEMBL170164 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1GAAHPGDUSP2 | |
| SCHEMBL16431209 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1GAAHPGDUSP2 | |
| SCHEMBL29368070 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1GAAHPGDUSP2 | |
| SCHEMBL16431027 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1GAAHPGDUSP2 | |
| SCHEMBL16431372 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1GAAHPGDUSP2 | |
| SCHEMBL16433240 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1GAAHPGDUSP2 | |
| SCHEMBL16432811 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1GAAHPGDUSP2 | |
| Methane SCHEMBL28127790 | 0.98 | KDM4E (0.53) | KDM4EALDH1A1GAAHPGDUSP2 | |
| SCHEMBL6239656 | 0.98 | KDM4E (0.52) | KDM4EALDH1A1GAAHPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10139406-B2 | Alkyl quinolones as biomarkers of pseudomonas aeruginosa infection and uses thereof | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-11-27 | — | — | US | claimed |
| US-20120294826-A1 | METHODS, KITS AND COMPOSITIONS FOR AMELIORATING ADVERSE EFFECTS ASSOCIATED WITH TRANSFUSION OF AGED RED BLOOD CELLS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-11-22 | — | — | US | claimed |
| EP-2442641-A1 | METHODS FOR AMELIORATING ADVERSE EFFECTS ASSOCIATED WITH TRANSFUSION OF AGED RED BLOOD CELLS | The Trustees of Columbia University in the City of New York (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2010147621-A1 | METHODS FOR AMELIORATING ADVERSE EFFECTS ASSOCIATED WITH TRANSFUSION OF AGED RED BLOOD CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-12-23 | — | — | WO | claimed |
| US-20070099889-A1 | Use of pseudan and pseudan inclusion bodies | GEORGE MASON INTELLECTUAL PROPERTIES, INC. | 2007-05-03 | — | — | US | claimed |
| WO-2007008769-A2 | USE OF PSEUDAN AND PSEUDAN INCLUSION BODIES | GEORGE MASON UNIVERSITY (US) | 2007-01-18 | — | — | WO | claimed |
| US-20030109548-A1 | Compositions and methods of treating iron excess | ROYT PAULETTE W (US) | 2003-06-12 | — | — | US | claimed |
| WO-2003041709-A1 | COMPOSITIONS AND METHODS OF TREATING IRON EXCESS | GEORGE MASON UNIVERSITY (US) | 2003-05-22 | — | — | WO | claimed |
| EP-3612528-B1 | FERROPORTIN-INHIBITOR SALTS | VIFOR INT AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| CN-110785417-B | Membrane iron transporter inhibitor salts | 威佛（国际）股份公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114668761-A | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-108290878-B | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11129820-B2 | Ferroportin-inhibitor salts | VIFOR (INTERNATIONAL) AG (CH) | 2021-09-28 | — | — | US | disclosed |
| WO-2007008769-A2 | USE OF PSEUDAN AND PSEUDAN INCLUSION BODIES | GEORGE MASON UNIVERSITY (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2005069989-A2 | METHODS FOR IDENTIFYING CANDIDATE COMPOUNDS FOR TREATING, REDUCING, OR PREVENTING PATHOGENIC INFECTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20030109548-A1 | Compositions and methods of treating iron excess | ROYT PAULETTE W (US) | 2003-06-12 | — | — | US | disclosed |
| WO-2003041709-A1 | COMPOSITIONS AND METHODS OF TREATING IRON EXCESS | GEORGE MASON UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-1995028929-A1 | AMINOLINE-N-OXIDE ANTIMICROBIALS FOR USE AGAINST H. PYLORI INFECTIONS | RPMS TECHNOLOGY LIMITED (GB) | 1995-11-02 | — | — | WO | disclosed |
| WO-1995028929-A1 | AMINOLINE-N-OXIDE ANTIMICROBIALS FOR USE AGAINST H. PYLORI INFECTIONS | RPMS TECHNOLOGY LIMITED (GB) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294826-A1 | METHODS, KITS AND COMPOSITIONS FOR AMELIORATING ADVERSE EFFECTS ASSOCIATED WITH TRANSFUSION OF AGED RED BLOOD CELLS | TFRC, FTH1, FECH | KDM4E 3273/4885ALDH1A1 477/4885GAA 140/4885 |
| US-10139406-B2 | Alkyl quinolones as biomarkers of pseudomonas aeruginosa infection and uses thereof | NQO2, QARS1, CD14 | KDM4E 4049/4885ALDH1A1 1222/4885GAA 1539/4885 |
| US-20070099889-A1 | Use of pseudan and pseudan inclusion bodies | MMP8, ETF1, MMP1 | KDM4E 3129/4885ALDH1A1 3910/4885GAA 458/4885 |
| US-11129820-B2 | Ferroportin-inhibitor salts | SLC40A1, HAMP, FECH | KDM4E 4775/4885ALDH1A1 1331/4885GAA 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.